
Metagenomi Inc (MGX) Stock Forecast & Price Target
Metagenomi Inc (MGX) Analyst Ratings
Bulls say
Metagenomi Inc. has developed a comprehensive metagenomics-derived genome editing toolbox that facilitates a range of genetic modifications, positioning the company as a significant player in the genetic medicines sector. The company’s pipeline includes promising product candidates targeting serious disorders such as Hemophilia A, which demonstrated durable Factor VIII levels of 80% over a 19-month period in non-human primate studies, indicating potential therapeutic effectiveness. With a strategic focus on vivo gene editing and technology out licensing for ex vivo cell therapy, Metagenomi is well-positioned to leverage its innovative capabilities to capture market opportunities in the evolving field of genetic medicine.
Bears say
Metagenomi Inc. reported a net loss of $19.9 million, or $0.54 per share, for the second quarter of 2025, reflecting ongoing financial challenges as the company invests in its gene editing pipeline. The company is trading significantly below its cash value, which presents potential upside; however, several risks loom, including potential delays in advancing clinical candidates and the inability to generate favorable data from key programs, particularly those targeting Hemophilia A. Additionally, there is a concern regarding possible long-term dilution, which could further impact shareholder value and sentiment toward the stock.
This aggregate rating is based on analysts' research of Metagenomi Inc and is not a guaranteed prediction by Public.com or investment advice.
Metagenomi Inc (MGX) Analyst Forecast & Price Prediction
Start investing in Metagenomi Inc (MGX)
Order type
Buy in
Order amount
Est. shares
0 shares